Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Nuevolution in connection with its listing on Nasdaq Stockholm
Mandate

Vinge advises Nuevolution in connection with its listing on Nasdaq Stockholm

June 25, 2018 Capital Markets and Public M&A

Vinge advises Nuevolution AB (publ) in connection with its list change from Nasdaq First North Premier to Nasdaq Stockholm’s main market.

The prospectus was published on 20 June 2018 and the trading on Nasdaq Stockholm commenced on 25 June 2018.
 
Nuevolution AB (publ) is a small molecule drug discovery biotech company. The company was founded in 2001 and is headquartered in Copenhagen, Denmark. 
 
Vinge’s team has primarily consisted of Dain Hård Nevonen, David Andersson, Maria Schultzberg, Nils Fredrik Dehlin, Malte Hedlund, Anna Thoms, Klara Secher and Victor Ericsson.

Related

Vinge advises Smart Eye Aktiebolag (publ) on its first SEK 300 million bond issue

 Vinge has advised Smart Eye Aktiebolag (publ) (“Smart Eye”) on the company’s first issue of senior unsecured bonds in an aggregate principal amount of SEK 300 million, under a framework of up to SEK 600 million. Skandinaviska Enskilda Banken AB (publ) acted as sole bookrunner in connection with the bond issue.
December 12, 2025

Vinge advises Nordstjernan in connection with the investment in Circura Group

Vinge has advised Nordstjernan in connection with its investment in newly established Circura Group.
December 12, 2025

Vinge has advised Axcel VI and Currentum in connection with the acquisition of Klarins Rör

 Vinge has advised Axcel VI and the Currentum Group in connection with the acquisition of Klarins Rör i Göteborg AB (“Klarins Rör”).
December 09, 2025